Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is between 18-50 years old.~2. After 12 weeks gestation.~3. Diagnosed with ITP meeting the diagnostic criteria for immune thrombocytopenia.~4. Patients who have no response or relapsed after Corticosteroid or IVIG.~5. Patients developed refractoriness to platelet transfusion.~6. To show a platelet count \< 30×10\^9/L, and with bleeding manifestations.~7. Willing and able to sign written informed consent.~Exclusion Criteria:~1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit.~2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit.~3. Current HIV infection or hepatitis B virus or hepatitis C virus infections.~4. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)~5. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.~6. Patients who are deemed unsuitable for the study by the investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- rhTPO (Type: EXPERIMENTAL): rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).